bioAffinity Technologies News Update
February 21 2024 - 8:00AM
Business Wire
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a
biotechnology company focused on the need for noninvasive tests for
the detection of early-stage cancer and lung disease, provides a
summary of recent Company news.
Lung Innovations Network Adds CyPath® Lung Test to its
Comprehensive Lung Care Practice
Lung Innovations Network is incorporating CyPath® Lung, our
noninvasive test for the early detection of lung cancer, into its
patient-centered practice that offers comprehensive lung care to
more than 10,000 patients in central and western Pennsylvania. Lung
Innovations Network’s multidisciplinary team focuses on affordable,
innovative and individualized care by incorporating new
technologies and research into an evidence-based practice. “I see
hundreds of patients a year in my clinical practice who can
directly benefit from CyPath® Lung, bioAffinity’s patient-friendly,
noninvasive test for lung cancer,” Medical Director Sandeep Bansal,
M.D., said.
bioAffinity Expands Sales Team for CyPath® Lung
National Sales Director Dallas Coleman announced that Cole
Koeppen has joined bioAffinity Technologies as Pulmonary Sales
Executive for CyPath® Lung in North Texas. Cole most recently was
Territory Sales Associate for Pulmonx Corporation, a provider of
minimally invasive treatments for patients with chronic obstructive
pulmonary disease (COPD). Prior to Pulmonx, Koeppen was Associate
Territory Manager for Becton Dickinson & Company (BD), a global
medical technology company. “Cole’s track record with both Pulmonx
and BD demonstrates his talent for developing effective sales
strategies, building long-term relationships with customers and
meeting aggressive targets,” said Dallas. “I look forward to
working with Cole to continue to expand our market share in North
Texas.”
Sandeep Bansal, M.D., Joins bioAffinity Medical and
Scientific Advisory Board
bioAffinity Technologies welcomes Dr. Bansal, Medical Director
of Lung Innovations Network, to our Medical and Scientific Advisory
Board. Board certified in pulmonary disease, critical care medicine
and interventional pulmonology, Dr. Bansal has also served as
principal investigator of multiple clinical research trials and
peer reviewer for several medical journals. “Dr. Bansal’s
experience as both clinician and researcher demonstrates his
commitment to innovative healthcare and the best possible outcome
for his patients,” bioAffinity Technologies President and CEO Maria
Zannes said. “He will be a valuable voice on our advisory
board.”
bioAffinity To Present at American Thoracic Society’s Annual
Conference
bioAffinity Staff Scientist Lydia Bederka, Ph.D., will present
her research, “Sputum Versus Bronchoalveolar Lavage (BAL) Fluid on
a Flow Cytometric Platform,” at the 2024 American Thoracic Society
(ATS) International Conference in San Diego from May 17-22, 2024.
The research is focused on adapting the successful CyPath® Lung
protocol, which detects cell populations in sputum that are
indicative of lung cancer, to analyze BAL fluid obtained by
bronchoscopy for the same purpose, the detection of lung cancer.
The ATS conference brings 14,000 clinicians and researchers in
pulmonology, critical care and sleep medicine together to share
ideas and innovations.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung and broad-spectrum cancer treatment. The Company’s first
product, CyPath® Lung, is a noninvasive test that has shown high
sensitivity and specificity for the detection of early-stage lung
cancer. CyPath® Lung is marketed as a Laboratory Developed Test
(LDT) by Precision Pathology Laboratory Services, a subsidiary of
bioAffinity Technologies, Inc. For more information, visit
www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X
(Twitter).
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of the federal
securities laws. Words such as "may," "might," "will," "should,"
"believe," "expect," "anticipate," "estimate," "continue,"
"predict," "forecast," "project," "plan," "intend" or similar
expressions, or statements regarding intent, belief, or current
expectations, are forward-looking statements. These forward-looking
statements are based upon current estimates and assumptions and
include statements regarding continuing to expand the Company’s
market share in North Texas, patients directly benefitting from
CyPath® Lung and the contributions to be made by Mr. Koeppen and
Dr. Bansal. These forward-looking statements are subject to various
risks and uncertainties, many of which are difficult to predict
that could cause actual results to differ materially from current
expectations and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the ability to expand the Company’s market
share, the ability to derive contributions from Mr. Koeppen and Dr.
Bansal, and the other factors discussed in the Company’s Annual
Report on Form 10-K for the year ended December 31, 2022, and its
subsequent filings with the SEC, including subsequent periodic
reports on Forms 10-Q and 8-K. Such forward-looking statements are
based on facts and conditions as they exist at the time such
statements are made and predictions as to future facts and
conditions. While the Company believes these forward-looking
statements are reasonable, readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. The information in this release is provided only as of
the date of this release, and the Company does not undertake any
obligation to update any forward-looking statement relating to
matters discussed in this press release, except as may be required
by applicable securities laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221772695/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
Investor Relations Dave Gentry RedChip Companies Inc.
1-800-RED-CHIP (733-2447) Or 407-491-4498 BIAF@redchip.com
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jun 2024 to Jul 2024
bioAffinity Technologies (NASDAQ:BIAF)
Historical Stock Chart
From Jul 2023 to Jul 2024